biostudies-literatureUnknown8(9)Smith GHRViiV Healthcare and Janssen Research and Development<h4>Background</h4>In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2) phase 2b study, long-acting (LA) injectable cabotegravir + rilpivirine dosed every 8 weeks (Q8W) or every 4 weeks (Q4W) demonstrated comparable efficacy with daily oral antiretroviral therapy (ART) through 96 weeks in ART-naive adults with human immunodeficiency virus type 1 (HIV-1). Here we report efficacy, tolerability, and safety of cabotegravir + rilpivirine LA over approximately 5 years.<h4>Methods</h4>After 20 weeks of oral cabotegravir + abacavir/lamivudine, participants were randomized to cabotegravir + rilpivirine LA Q8W or Q4W or continue oral ART through the 96-week maintenance period. In the extension period through week 256, participants continued their current LA regimen (randomized Q8W/Open forum infectious diseasesofab439https://www.ebi.ac.uk/biostudies/studies/S-EPMC8454521biostudies-literatureEfficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.PMC8454521Henry WKZhang FKhuong-Josses MAPodzamczer DSmith KYStellbrink HJMargolis DAJaeger HMasia MDMYazdanpanah YMcCoig CCSmith GHRBettacchi CJArasteh KVan Solingen-Ristea RRichmond GJVandermeulen KSt Clair MHSpreen WRMontes-Ramirez MLSutton KCfalseEfficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.<h4>Background</h4>In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2) phase 2b study, long-acting (LA) injectable cabotegravir + rilpivirine dosed every 8 weeks (Q8W) or every 4 weeks (Q4W) demonstrated comparable efficacy with daily oral antiretroviral therapy (ART) through 96 weeks in ART-naive adults with human immunodeficiency virus type 1 (HIV-1). Here we report efficacy, tolerability, and safety of cabotegravir + rilpivirine LA over approximately 5 years.<h4>Methods</h4>After 20 weeks of oral cabotegravir + abacavir/lamivudine, participants were randomized to cabotegravir + rilpivirine LA Q8W or Q4W or continue oral ART through the 96-week maintenance period. In the extension period through week 256, participants continued their current LA regimen (randomized Q8W/2021-01-01T00:00:00Z2021 Sep2025-04-26T23:36:13.501Z2022-02-11T11:16:19.681ZS-EPMC84545213455756310.1093/ofid/ofab439